Amgen cholesterol drug cuts heart attack, stroke risk but shares fall

By Bill BerkrotWASHINGTON (Reuters) - Amgen Inc's$14,000 cholesterol drug Repatha cut the risk of heart attack and stroke by over 20 percent in patients with heart disease, but results from a highly-anticipated study fell short of investor expectations and shares dropped 6 percent.The date unveiled on Friday demonstrated a clinical benefit beyond the drug's known ability to slash "bad" LDL cholesterol levels, but came in below high investor expectations.